Is Apellis Pharmaceuticals, Inc. (APLS) a Buy, Sell, or Hold?
NASDAQ : APLS
Apellis Pharmaceuticals, Inc.
$41.03 USD
$0 (0.0%)
- Volume
- 28.64M
- Average Volume
- 6.37M
- Market Capitalization
- $5.25B
- P/E Ratio
- 38.71
- Dividend Yield
- 0.00%
- Price Target
- $32.50
- Year High
- $41.14
- Year Low
- $16.61
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $3.63
Company Overview
NASDAQ
Cedric Francois
Biotechnology
Healthcare
APLS
705
US
USD
Liquidity Metrics
1.15
3.63
3.16
1.43
0.00
Sales & Valuation
$1B
4.75
12.46
139.04
0.30
Profitability
$0.18
$22.39M
12.06%
12.23%
39.71%
12.31%
P/E Metrics
38.71
0.07
0.07
Analyst Price Target & Rating
$32.50
$41.00
$24.00
0/5
25 Analysts
26.25%
Poll Results
About Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Stock
Apellis Pharmaceuticals, Inc. is an actively operating biopharmaceutical enterprise dedicated to the discovery, advancement, and commercialization of therapeutic agents. Its core strategy involves modulating the complement system to address various autoimmune and inflammatory conditions. The company's primary investigational compound, pegcetacoplan, is currently undergoing Phase III clinical evaluation. This advanced-stage therapy is being explored for its potential in treating geographic atrophy (GA), a form of age-related macular degeneration, and paroxysmal nocturnal hemoglobinuria (PNH). Beyond this lead candidate, Apellis also offers EMPAVELI (a systemic formulation of pegcetacoplan), which is being developed for a range of indications: in hematology for cold agglutinin disease (CAD) ... and thrombotic microangiopathy associated with hematopoietic stem cell transplantation (HSCT-TMA); in nephrology for C3 glomerulopathy (C3G) and immune complex membranoproliferative glomerulonephritis (IC-MPGN); and in neurology for amyotrophic lateral sclerosis (ALS). Furthermore, Apellis boasts a diverse pipeline including APL-2006, a dual-action C3 and VEGF inhibitor designed for complement-mediated disorders; APL-1030, a C3 inhibitor targeting multiple neurodegenerative diseases; and a novel combination therapy involving EMPAVELI with small interfering RNA (siRNA) to reduce hepatic C3 protein synthesis. Strategic alliances play a significant role, with a collaboration and licensing agreement in place with Swedish Orphan Biovitrum AB (publ) for the joint development of pegcetacoplan. The company also maintains a research partnership with Beam Therapeutics Inc., focusing on leveraging Beam's base editing technology to uncover new treatments for illnesses driven by complement system dysregulation. Established in 2009, Apellis Pharmaceuticals, Inc. operates from its headquarters in Waltham, Massachusetts.
Biogen scales back Apellis programs, trims research roles after $5.6 billion buyout
2026-06-26 09:25:41
Biogen said on Friday it had either paused or discontinued funding for most of Apellis Pharmaceuticals' research programs as it integrates the rare-disease drugs specialist it purchased for $5.6 billion earlier this year.
2026-05-31 09:00:00
[url="]Pfizer Inc. [/url](NYSE: PFE) today announced detailed progression-free and overall survival results from Cohort 3, a randomized cohort of the Phase 3 B
2026-05-30 09:00:00
[url="]Pfizer Inc. [/url](NYSE: PFE) today announced detailed results from the pivotal Phase 3 TALAPRO-3 study of TALZENNAÂ (talazoparib), an oral poly ADP-ri
Bright Horizons Family Solutions and Remitly Global Set to Join S&P SmallCap 600
2026-05-07 18:01:00
NEW YORK, May 7, 2026 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P SmallCap 600 effective prior to the opening of trading on Thursday, May 14: Bright Horizons Family Solutions Inc. (NYSE: BFAM) will replace Tri Pointe Homes Inc. (NYSE: TPH). Sumitomo Forestry Group (TSE: 1911) is acquiring Tri Pointe Homes in a deal expected to close soon, pending final closing conditions.
Compared to Estimates, Apellis Pharmaceuticals (APLS) Q1 Earnings: A Look at Key Metrics
2026-05-07 17:00:21
The headline numbers for Apellis Pharmaceuticals (APLS) give insight into how the company performed in the quarter ended March 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Apellis Pharmaceuticals, Inc. (APLS) Tops Q1 Earnings and Revenue Estimates
2026-05-07 16:26:02
Apellis Pharmaceuticals, Inc. (APLS) came out with quarterly earnings of $0.15 per share, beating the Zacks Consensus Estimate of a loss of $0.38 per share. This compares to a loss of $0.74 per share a year ago.
$HAREHOLDER ALERT: The M&A Class Action Firm Is Investigating The Merger—CZNL, HLX, APLS, and SLNO
2026-05-05 11:09:00
NEW YORK, May 05, 2026 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2025 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating
Biogen Beats Q1 Earnings Estimates but Cuts 2026 EPS View on M&A Costs
2026-04-29 11:21:07
Biogen beats Q1 earnings and revenue estimates, fueled by new drug growth, but cuts 2026 EPS outlook to reflect M&A costs.
Frequently Asked Questions
-
What is the current Apellis Pharmaceuticals, Inc. (APLS) stock price?
-
Apellis Pharmaceuticals, Inc.(NASDAQ:APLS) stock price is $41.03 in the last trading session. During the trading session, APLS stock reached the peak price of $41.14 while $16.61 was the lowest point it dropped to. The percentage change in APLS stock occurred in the recent session was 0.0% while the dollar amount for the price change in APLS stock was $0.
-
APLS's industry and sector of operation?
-
The NASDAQ listed APLS is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of APLS?
-
Pascal Deschatelets | Co-Founder & Chief Scientific Officer
James G. Chopas | Vice President, Corporate Controller & Chief Accounting Officer
Philip Ferrone | Chief Medical Retina Advisor
Alec Machiels | Co-Founder & Director
Eva Stroynowski | Head of Investor Relations -
How many employees does APLS have?
-
Number of APLS employees currently stands at 705. APLS operates from 100 Fifth Avenue, Waltham, MA 02451, US.
-
Link for APLS official website?
-
Official Website of APLS is: https://www.apellis.com
-
How do I contact APLS?
-
APLS could be contacted at phone #617 977 5700 and can also be accessed through its website. APLS operates from 100 Fifth Avenue, Waltham, MA 02451, US.
-
How many shares of APLS are traded daily?
-
The average number of APLS shares traded daily for last 3 months was 6.37M.
-
What is the market cap of APLS currently?
-
The market value of APLS currently stands at $5.25B with its latest stock price at $41.03